iRhythm to acquire VitalConnect for $287.5m in cash and stock
iRhythm Holdings has agreed to acquire VitalConnect, a privately held wearable biosensor company, for total consideration of approximately $287.5 million. The deal comprises roughly $237.5 million in cash, to be funded from iRhythm's existing balance sheet, and approximately $50 million in iRhythm common stock. The transaction is expected to close before the end of 2026, subject to regulatory clearance and customary closing conditions.
The acquisition broadens iRhythm's portfolio beyond its flagship Zio patch, which is focused on ambulatory cardiac monitoring, into mobile cardiac telemetry (MCT), inpatient monitoring and hospital-to-home care. VitalConnect's FDA-cleared platform supports multiple monitoring modalities and can track up to 11 physiological parameters simultaneously, adding continuous multi-vitals capability that iRhythm does not currently offer at scale.
The deal rationale
Quentin Blackford, iRhythm's president and chief executive, said the combination represents "a significant next step in iRhythm's evolution from ambulatory cardiac monitoring to a broader cardiac monitoring and intelligence platform." He described VitalConnect's MCT, multi-vitals and hospital monitoring capabilities as complementary to Zio and said the combined commercial infrastructure should accelerate growth and deepen relationships with health systems.
VitalConnect's platform features up to 30-day patient monitoring, four-in-one functionality and AI-enabled algorithms, and is designed for flexible service models across remote and inpatient settings. iRhythm will also provide VitalConnect with interim working capital financing of up to $30 million while the deal progresses toward closing, with an initial tranche of $10 million.
The company said the transaction is expected to be accretive to its revenue growth rate from 2027 onwards, while maintaining its previously stated adjusted EBITDA margin target of 15% for that year. No reconciliation of that non-GAAP target was provided, as iRhythm said certain inputs remain outside its control.
Market context
The cardiac monitoring wearables market has expanded rapidly in recent years as payers and health systems seek cost-effective alternatives to traditional Holter monitors and in-hospital telemetry. MCT, which allows clinicians to review real-time data remotely, has attracted particular interest as a higher-reimbursement category where several competitors, including BioTelemetry (now part of Philips) and CardioNet, have built substantial businesses.
iRhythm has historically concentrated on the longer-duration patch monitoring segment, where its Zio device holds a strong position. By stepping into MCT and inpatient monitoring through VitalConnect, it moves into territory already occupied by established players, meaning commercial execution and integration of sales teams will be closely watched. The inclusion of iRhythm stock as part of the consideration aligns VitalConnect's existing stakeholders with the combined company's performance, a structure that typically signals both acquirer confidence and a degree of negotiating balance.
Goldman Sachs acted as exclusive financial adviser to iRhythm, with Fenwick and West as legal counsel. No adviser for VitalConnect was disclosed in the release.
Investors will focus on the pace of cross-selling into existing iRhythm health system accounts, the timeline for integrating VitalConnect's cloud-based workflows with iRhythm's Zio platform, and whether the MCT reimbursement environment remains favourable as CMS continues to review remote monitoring codes.